AtriCure (NASDAQ:ATRC) Updates Q4 2025 Earnings Guidance

AtriCure (NASDAQ:ATRC) issued an update on its fourth quarter 2025 earnings guidance on Monday morning. The company provided earnings per share guidance of -0.210–0.180 for the period, compared to the consensus earnings per share estimate of -0.050. The company issued revenue guidance of $140.5 million-$140.5 million, compared to the consensus revenue estimate of $139.2 million. AtriCure also updated its FY 2025 guidance to EPS.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ATRC. JPMorgan Chase & Co. increased their price objective on AtriCure from $42.00 to $48.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Citigroup reiterated a “market outperform” rating on shares of AtriCure in a research note on Thursday, October 30th. Zacks Research upgraded AtriCure from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 6th. Canaccord Genuity Group upped their price objective on shares of AtriCure from $53.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AtriCure in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, AtriCure has an average rating of “Moderate Buy” and a consensus price target of $52.44.

AtriCure Price Performance

AtriCure stock traded down $2.74 during midday trading on Monday, reaching $38.72. 231,609 shares of the stock were exchanged, compared to its average volume of 424,586. AtriCure has a 52 week low of $28.29 and a 52 week high of $43.18. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.85 and a current ratio of 3.87. The firm has a market cap of $1.93 billion, a PE ratio of -63.47 and a beta of 1.40. The company’s fifty day moving average is $37.67 and its 200-day moving average is $35.78.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Wednesday, October 29th. The medical device company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.10. The firm had revenue of $134.27 million for the quarter, compared to analysts’ expectations of $131.25 million. AtriCure had a negative net margin of 5.55% and a negative return on equity of 2.54%. The business’s quarterly revenue was up 15.8% on a year-over-year basis. During the same quarter last year, the company posted ($0.17) EPS. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. On average, sell-side analysts forecast that AtriCure will post -0.6 EPS for the current year.

Insider Activity at AtriCure

In other news, insider Justin J. Noznesky sold 5,166 shares of AtriCure stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $37.29, for a total transaction of $192,640.14. Following the sale, the insider owned 78,798 shares of the company’s stock, valued at approximately $2,938,377.42. The trade was a 6.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Maggie Yuen sold 3,000 shares of the business’s stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $35.72, for a total transaction of $107,160.00. Following the transaction, the director owned 11,371 shares in the company, valued at $406,172.12. This represents a 20.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 18,166 shares of company stock worth $676,378 in the last three months. 3.50% of the stock is owned by insiders.

Hedge Funds Weigh In On AtriCure

A number of hedge funds have recently bought and sold shares of ATRC. Wellington Management Group LLP increased its position in shares of AtriCure by 8.1% during the 3rd quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company’s stock valued at $151,296,000 after purchasing an additional 322,818 shares during the last quarter. Goldman Sachs Group Inc. grew its position in AtriCure by 1.0% during the first quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company’s stock valued at $27,830,000 after buying an additional 8,956 shares during the period. Dimensional Fund Advisors LP increased its holdings in AtriCure by 3.7% during the third quarter. Dimensional Fund Advisors LP now owns 850,556 shares of the medical device company’s stock valued at $29,980,000 after buying an additional 30,448 shares during the last quarter. Bank of America Corp DE raised its position in AtriCure by 2.1% in the third quarter. Bank of America Corp DE now owns 724,955 shares of the medical device company’s stock worth $25,555,000 after acquiring an additional 14,782 shares during the period. Finally, Wasatch Advisors LP raised its position in AtriCure by 3.1% in the second quarter. Wasatch Advisors LP now owns 506,822 shares of the medical device company’s stock worth $16,609,000 after acquiring an additional 15,250 shares during the period. Institutional investors own 99.11% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.